REFERENCES
- Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40(2)255–263, [INFOTRIEVE], [CSA]
- Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1–85, [INFOTRIEVE], [CSA]
- Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65(1)128–135, [INFOTRIEVE], [CSA]
- Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in β-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84(3)113–117, [INFOTRIEVE], [CSA]
- Wilce MC, Parker MW. Structure and function of glutathione S-transferases. Biochim Biophys Acta 1994; 1205(1)1–18, [INFOTRIEVE], [CSA]
- Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, D'Anna R, Bongiorno A. Oxidative stress and antioxidant status in β-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996; 88(9)3608–3614, [INFOTRIEVE], [CSA]
- Yang Y, Kao MT, Chang CC, Chung SY, Chen CM, Tsai JJ, Chang JG. Glutathione S-transferase T1 deletion is a risk factor for developing end-stage renal disease in diabetic patients. Int J Mol Med 2004; 14(5)855–859, [INFOTRIEVE], [CSA]
- Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with β-thalassemia major. Ann Hematol 2004; 83(12)779–783, [INFOTRIEVE], [CROSSREF], [CSA]
- Chen CM, Chang JG, Ko YC. Ethnic variation in CYP2E1, GSTM1, GSTT1 genes polymorphism analysis: Taiwan aborigines, Thai and Filipino. Mid Taiwan J Med 2000; 5(3)181–188, [CSA]
- Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A. Oxidant, antioxidant status and metabolic data in patients with β-thalassemia. Clin Chim Acta 2003; 338(1–2)79–86, [INFOTRIEVE], [CROSSREF], [CSA]
- Meral A, Tuncel P, Surmen-Gur E, Ozbek R, Ozturk E, Gunay U. Lipid peroxidation and antioxidant status in β-thalassemia. Pediatr Hematol Oncol 2000; 17(8)687–693, [INFOTRIEVE], [CROSSREF], [CSA]
- Reller K, Dresow B, Collell M, Fischer R, Engelhardt R, Nielsen P, Durken M, Politis C, Piga A. Iron overload and antioxidant status in patients with β-thalassemia major. Ann NY Acad Sci 1998; 850: 463–465, [INFOTRIEVE], [CROSSREF], [CSA]
- Kolnagou A, Fessas C, Papatryphonas A, Economides C, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol 2004; 127(3)360–361, [INFOTRIEVE], [CROSSREF], [CSA]
- Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6)392–397, [INFOTRIEVE], [CROSSREF], [CSA]